Literature DB >> 15120486

The inflow and outflow of anti-glaucoma drugs.

David F Woodward1, Daniel W Gil.   

Abstract

The treatment of glaucoma by reducing intraocular pressure has relied traditionally on inhibiting aqueous humor secretion (inflow). However, recent therapeutic approaches have targeted aqueous humor outflow. Prostanoid FP receptor agonists selectively increase uveoscleral outflow and the prostamide analog bimatoprost alters trabecular and uveoscleral outflow. An emerging therapeutic strategy is direct neuroprotection of retinal ganglion cells, which are selectively lost in glaucoma.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15120486     DOI： 10.1016/j.tips.2004.03.002

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN： 0165-6147            Impact factor:   14.819


  10 in total

1.  Physical and functional interaction between CB1 cannabinoid receptors and beta2-adrenoceptors.

Authors:  Brian D Hudson; Terence E Hébert; Melanie E M Kelly
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

2.  RGS2-deficient mice exhibit decreased intraocular pressure and increased retinal ganglion cell survival.

Authors:  Miyuki Inoue-Mochita; Toshihiro Inoue; David L Epstein; Kendall J Blumer; Ponugoti V Rao
Journal:  Mol Vis       Date:  2009-03-06       Impact factor: 2.367

3.  Endogenous Bioactive Lipids and the Regulation of Conventional Outflow Facility.

Authors:  Zhou Wan; David F Woodward; W Daniel Stamer
Journal:  Expert Rev Ophthalmol       Date:  2008

4.  Eyedrops containing SA9000 prodrugs result in sustained reductions in intraocular pressure in rabbits.

Authors:  John J Arnold; Yash Choksi; Xin Chen; Atsushi Shimazaki; John Hatten; Eric J Toone; David L Epstein; Pratap Challa
Journal:  J Ocul Pharmacol Ther       Date:  2009-06       Impact factor: 2.671

5.  Differential volume regulation and calcium signaling in two ciliary body cell types is subserved by TRPV4 channels.

Authors:  Andrew O Jo; Monika Lakk; Amber M Frye; Tam T T Phuong; Sarah N Redmon; Robin Roberts; Bruce A Berkowitz; Oleg Yarishkin; David Križaj
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-22       Impact factor: 11.205

6.  Topical administration of adrenergic receptor pharmaceutics and nerve growth factor.

Authors:  Jena J Steinle
Journal:  Clin Ophthalmol       Date:  2010-07-21

7.  Does Long-Term Administration of a Beta-Blocker (Timolol) Induce Fibril-Based Cataract Formation In-vivo?

Authors:  Mohammad Reza Nikbakht; Mohammad Reza Ashrafi-Kooshk; Morteza Jaafari; Moosa Ghasemi; Reza Khodarahmi
Journal:  Iran J Pharm Res       Date:  2014       Impact factor: 1.696

8.  Role of prostaglandins and specific place in therapy of bimatoprost in the treatment of elevated intraocular pressure and ocular hypertension: A closer look at the agonist properties of bimatoprost and the prostamides.

Authors:  Scott D Smid
Journal:  Clin Ophthalmol       Date:  2009-12-29

Review 9.  Promising Approach in the Treatment of Glaucoma Using Nanotechnology and Nanomedicine-Based Systems.

Authors:  Fidiniaina Rina Juliana; Samuel Kesse; Kofi Oti Boakye-Yiadom; Hanitrarimalala Veroniaina; Huihui Wang; Meihao Sun
Journal:  Molecules       Date:  2019-10-22       Impact factor: 4.411

10.  Synergistic Effect of Acetazolamide-(2-hydroxy)propyl β-Cyclodextrin in Timolol Liposomes for Decreasing and Prolonging Intraocular Pressure Levels.

Authors:  Carmen M Arroyo-García; Daniela Quinteros; Santiago D Palma; Cesáreo J Jiménez de Los Santos; José R Moyano; Antonio M Rabasco; María Luisa González-Rodríguez
Journal:  Pharmaceutics       Date:  2021-11-25       Impact factor: 6.321
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.